Previous Article | Next Article 
Journal of Virology, January 2006, p. 821-834, Vol. 80, No. 2
0022-538X/06/$08.00+0 doi:10.1128/JVI.80.2.821-834.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Mutations on the External Surfaces of Adeno-Associated Virus Type 2 Capsids That Affect Transduction and Neutralization
Michael A. Lochrie,*
Gwen P. Tatsuno,
Brian Christie,
Jennifer Wellman McDonnell,
Shangzhen Zhou,
Richard Surosky,
Glenn F. Pierce, and
Peter Colosi
Avigen,
Inc., 1301 Harbor Bay Parkway, Alameda, California
94502-6541
Received 27 May 2005/
Accepted 24 October 2005
Mutations
were made at 64 positions on the external surface of the
adeno-associated virus type 2 (AAV-2) capsid in regions expected to
bind antibodies. The 127 mutations included 57 single alanine
substitutions, 41 single nonalanine substitutions, 27 multiple
mutations, and 2 insertions. Mutants were assayed for capsid synthesis,
heparin binding, in vitro transduction, and binding and neutralization
by murine monoclonal and human polyclonal antibodies. All mutants made
capsid proteins within a level about 20-fold of that made by the wild
type. All but seven mutants bound heparin as well as the wild type.
Forty-two mutants transduced human cells at least as well as the wild
type, and 10 mutants increased transducing activity up to ninefold more
than the wild type. Eighteen adjacent alanine substitutions diminished
transduction from 10- to 100,000-fold but had no effect on heparin
binding and define an area (dead zone) required for transduction that
is distinct from the previously characterized heparin receptor binding
site. Mutations that reduced binding and neutralization by a murine
monoclonal antibody (A20) were localized, while mutations that reduced
neutralization by individual human sera or by pooled human, intravenous
immunoglobulin G (IVIG) were dispersed over a larger area. Mutations
that reduced binding by A20 also reduced neutralization. However, a
mutation that reduced the binding of IVIG by 90% did not reduce
neutralization, and mutations that reduced neutralization by IVIG did
not reduce its binding. Combinations of mutations did not significantly
increase transduction or resistance to neutralization by IVIG. These
mutations define areas on the surface of the AAV-2 capsid that are
important determinants of transduction and antibody
neutralization.
* Corresponding
author. Present address: 3374 Creekview Court, Hayward, CA 94541-3581.
Phone: (510) 881-1478. Fax: (510) 748-7136. E-mail:
mlochrie{at}yahoo.com.
Journal of Virology, January 2006, p. 821-834, Vol. 80, No. 2
0022-538X/06/$08.00+0 doi:10.1128/JVI.80.2.821-834.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Mays, L. E., Vandenberghe, L. H., Xiao, R., Bell, P., Nam, H.-J., Agbandje-McKenna, M., Wilson, J. M.
(2009). Adeno-Associated Virus Capsid Structure Drives CD4-Dependent CD8+ T Cell Response to Vector Encoded Proteins. J. Immunol.
182: 6051-6060
[Abstract]
[Full Text]
-
Grimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B., Storm, T. A., Kay, M. A.
(2008). In Vitro and In Vivo Gene Therapy Vector Evolution via Multispecies Interbreeding and Retargeting of Adeno-Associated Viruses. J. Virol.
82: 5887-5911
[Abstract]
[Full Text]
-
DiPrimio, N., Asokan, A., Govindasamy, L., Agbandje-McKenna, M., Samulski, R. J.
(2008). Surface Loop Dynamics in Adeno-Associated Virus Capsid Assembly. J. Virol.
82: 5178-5189
[Abstract]
[Full Text]
-
Nam, H.-J., Lane, M. D., Padron, E., Gurda, B., McKenna, R., Kohlbrenner, E., Aslanidi, G., Byrne, B., Muzyczka, N., Zolotukhin, S., Agbandje-McKenna, M.
(2007). Structure of Adeno-Associated Virus Serotype 8, a Gene Therapy Vector. J. Virol.
81: 12260-12271
[Abstract]
[Full Text]
-
Govindasamy, L., Padron, E., McKenna, R., Muzyczka, N., Kaludov, N., Chiorini, J. A., Agbandje-McKenna, M.
(2006). Structurally Mapping the Diverse Phenotype of Adeno-Associated Virus Serotype 4. J. Virol.
80: 11556-11570
[Abstract]
[Full Text]
-
Wu, Z., Asokan, A., Grieger, J. C., Govindasamy, L., Agbandje-McKenna, M., Samulski, R. J.
(2006). Single Amino Acid Changes Can Influence Titer, Heparin Binding, and Tissue Tropism in Different Adeno-Associated Virus Serotypes. J. Virol.
80: 11393-11397
[Abstract]
[Full Text]
-
Jiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., Mingozzi, F., High, K. A., Pierce, G. F.
(2006). Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood
108: 3321-3328
[Abstract]
[Full Text]
-
Akache, B., Grimm, D., Pandey, K., Yant, S. R., Xu, H., Kay, M. A.
(2006). The 37/67-Kilodalton Laminin Receptor Is a Receptor for Adeno-Associated Virus Serotypes 8, 2, 3, and 9. J. Virol.
80: 9831-9836
[Abstract]
[Full Text]
-
Asokan, A., Hamra, J. B., Govindasamy, L., Agbandje-McKenna, M., Samulski, R. J.
(2006). Adeno-Associated Virus Type 2 Contains an Integrin {alpha}5{beta}1 Binding Domain Essential for Viral Cell Entry.. J. Virol.
80: 8961-8969
[Abstract]
[Full Text]